Suppr超能文献

肌脂肪变性和肌肉流失影响男性肝细胞癌患者的肝移植结局。

Myosteatosis and muscle loss impact liver transplant outcomes in male patients with hepatocellular carcinoma.

作者信息

Lu Di, Hu Zhihang, Chen Hao, Khan Abid Ali, Xu Qingguo, Lin Zuyuan, Li Huigang, Zhuo Jianyong, He Chiyu, Zhuang Li, Yang Zhe, Dong Siyi, Cai Jinzhen, Zheng Shusen, Xu Xiao

机构信息

Department of Hepatobiliary & Pancreatic Surgery and Minimally Invasive Surgery, Zhejiang Provincial People's Hospital, Affiliated People's Hospital of Hangzhou Medical College, Hangzhou, China.

NHC Key Laboratory of Combined Multi-organ Transplantation, Hangzhou, China.

出版信息

J Cachexia Sarcopenia Muscle. 2024 Oct;15(5):2071-2083. doi: 10.1002/jcsm.13554. Epub 2024 Aug 27.

Abstract

BACKGROUND

Sarcopenia is associated with unfavourable long-term survival in patients undergoing liver transplantation (LT) for hepatocellular carcinoma (HCC). However, the impact of myosteatosis and muscle loss on patient prognosis has not been investigated.

METHODS

Seven hundred fifty-six HCC patients who received LT at 3 transplant centres were included. Computed tomography (CT) images of recipients were collected to measure skeletal muscle index (SMI) and skeletal muscle radiodensity (SMRA). The impact of myosteatosis on the prognosis of sarcopenic and non-sarcopenic patients was studied separately. Muscle status was evaluated based on the presence of sarcopenia and myosteatosis. The muscle loss of 342 males was calculated as the relative change of SMI between pre- and post-LT evaluations. Cox regression models were used to identify predictors of overall survival (OS) and recurrence-free survival (RFS).

RESULTS

The study comprised 673 males and 83 females. The median follow-up time was 31 months (interquartile range, 19-43 months). Prior to LT, 267 (39.7%) and 187 (27.8%) males were defined as sarcopenic (low-SMI) and myosteatotic (low-SMRA), respectively. For sarcopenic recipients, the presence of myosteatosis was followed by a 23.6% decrease in 5 year OS (P < 0.001) and a 15.0% decrease in 5 year RFS (P = 0.014). Univariate and multivariate analyses revealed that muscle status was an independent predictor of OS [hazard ratio (HR), 1.569; 95% confidence interval (CI), 1.317-1.869; P < 0.001] and RFS (HR, 1.369; 95% CI, 1.182-1.586; P < 0.001). Postoperatively, a muscle loss >14.2% was an independent risk factor for poor OS (HR, 2.286; 95% CI, 1.358-3.849; P = 0.002) and RFS (HR, 2.219; 95% CI, 1.418-3.471; P < 0.001) in non-sarcopenic recipients (N = 209).

CONCLUSIONS

Pre-transplant myosteatosis aggravated the adverse impact of sarcopenia on liver transplant outcomes in male HCC patients. Post-transplant muscle loss might assist in prognostic stratification of recipients without pre-existing sarcopenia, intriguing new insights into individualized management.

摘要

背景

在接受肝细胞癌(HCC)肝移植(LT)的患者中,肌肉减少症与不良的长期生存相关。然而,肌少脂症和肌肉量减少对患者预后的影响尚未得到研究。

方法

纳入了在3个移植中心接受LT的756例HCC患者。收集受者的计算机断层扫描(CT)图像,以测量骨骼肌指数(SMI)和骨骼肌放射密度(SMRA)。分别研究了肌少脂症对肌肉减少症患者和非肌肉减少症患者预后的影响。根据是否存在肌肉减少症和肌少脂症评估肌肉状态。计算342例男性患者LT前后评估之间SMI的相对变化,以得出其肌肉量减少情况。采用Cox回归模型确定总生存(OS)和无复发生存(RFS)的预测因素。

结果

该研究包括673例男性和83例女性。中位随访时间为31个月(四分位间距,19 - 43个月)。LT前,分别有267例(39.7%)和187例(27.8%)男性被定义为肌肉减少症(低SMI)和肌少脂症(低SMRA)。对于肌肉减少症受者,存在肌少脂症后,5年OS降低23.6%(P < 0.001),5年RFS降低15.0%(P = 0.014)。单因素和多因素分析显示,肌肉状态是OS(风险比[HR],1.569;95%置信区间[CI],1.317 - 1.869;P < 0.001)和RFS(HR,1.369;95% CI,1.182 - 1.586;P < 0.001)的独立预测因素。术后,肌肉量减少>14.2%是非肌肉减少症受者(N = 209)OS不良(HR,2.286;95% CI,1.358 - 3.849;P = 0.002)和RFS不良(HR,2.219;95% CI,1.418 - 3.471;P < 0.001)的独立危险因素。

结论

移植前肌少脂症加重了男性HCC患者肌肉减少症对肝移植结局的不利影响。移植后肌肉量减少可能有助于对无术前肌肉减少症的受者进行预后分层,为个体化管理提供了新的有趣见解。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8d17/11446693/853f23efc287/JCSM-15-2071-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验